XML 124 R30.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Reconciliation of Cash and Cash Equivalents
The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):

December 31,
20202019
Cash and cash equivalents $2,623,850 $235,876 
Restricted cash1,032 1,032 
Restricted cash, non-current 11,053 10,791 
Total cash, cash equivalents and restricted cash shown in the consolidated
statements of cash flows
$2,635,935 $247,699 
Reconciliation of Restricted Cash
The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):

December 31,
20202019
Cash and cash equivalents $2,623,850 $235,876 
Restricted cash1,032 1,032 
Restricted cash, non-current 11,053 10,791 
Total cash, cash equivalents and restricted cash shown in the consolidated
statements of cash flows
$2,635,935 $247,699 
Entities that Accounted for More than 10% of Total Revenue and Accounts Receivable
A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:
Percentage of Revenue
Years Ended December 31,
Percentage of 
Accounts Receivable
December 31,
20202019201820202019
Merck
*61 %49 %*13 %
BARDA
65 %13 %*22 %54 %
Vertex
*10 %**17 %
AstraZeneca
**34 %**
U.S. Government (excluding BARDA)24 %****
European Commission***28 %*
United Kingdom Government***11 %*
South Korea Government***24 %*
________
* - Represents an amount of less than 10%
Estimated Useful Lives of Property and Equipment The estimated useful lives of property and equipment are described below:
Estimated Useful Life
Laboratory equipment
5 years
Leasehold improvements
Lesser of estimated useful life of improvement
or remaining life of related lease
Computer equipment and software
3 years
Internally developed software3 years
Furniture, fixtures and other5 years
Right of use asset, financing
Lease term
Property and equipment, net as of December 31, 2020 and 2019 consists of the following (in thousands):
December 31,
20202019
Laboratory equipment
$120,714 $108,257 
Leasehold improvements179,901 152,426 
Furniture, fixtures and other4,662 3,316 
Computer equipment and software
13,398 11,985 
Internally developed software
7,020 7,020 
Right-of-use asset, financing
56,348 9,853 
Construction in progress
34,507 3,222 
416,550 296,079 
Less: Accumulated depreciation
(119,661)(94,584)
Property and equipment, net
$296,889 $201,495 
Components of Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive gain (loss) for the years ended December 31, 2020 and 2019 are as follows (in thousands): 
Unrealized Gain on Available-for-Sale Debt Securities
Accumulated other comprehensive loss, balance at December 31, 2018$(1,320)
Other comprehensive income3,124 
Accumulated other comprehensive gain, balance at December 31, 20191,804 
Other comprehensive income1,200 
Accumulated other comprehensive gain, balance at December 31, 2020$3,004